4B Technologies, Ltd

4B Technologies was founded with a mission to develop novel medicines for neurodegenerative diseases and neurological injuries. With deep expertise in neuroscience and CNS drug discovery, we have developed a strategic framework to overcome the key challenges in CNS drug research and development. Our approach addresses targeting strategy, animal model development, basic-to-clinical translation, biomarkers, and clinical trial design. Through our in-house drug discovery efforts and strategic alliances with academic and industrial partners, 4B Technologies is advancing a pipeline of innovative medicines into the clinic to validate their therapeutic potential. Our goal is to become a global leader in developing breakthrough treatments for neurological diseases. 4B Technologies was registered in the Cayman Islands and Hong Kong in 2017 and began full operations in 2018. Our preclinical R&D is based in Suzhou, with clinical development teams in Beijing and Shanghai, and a business development unit in San Diego, California.